Abstract:I have argued that early human embryos are not human beings, and do not have normal rights. Like human sperm and ova, they are both alive and biologically human. However, they lack the physiological development necessary to sustain a capacity for sentience. If Ford is right, then they are not yet individual human organisms. But the more important point is that their lack of a capacity for sentience makes them inappropriate candidates for the ascription of moral rights. Thus, research on human embryos produced in vitro is not a wrong against them--at least so long as experimentally manipulated embryos are not returned to the womb, or artificially gestated to a stage at which they might become sentient. Some of the more difficult issues about embryo experimentation involve the rights of women as experimental subject and donors. The consent of both male and female gamete donors should normally be required for the production or experimental use of IVF embryos. (Possible exceptions might include cases in which one or both progenitors have died, and the survivor or other responsible family member wished to donate the (frozen) IVF embryos for research or other uses.) However, it is women's rights that are most apt to be endangered, for example, if the large scale therapeutic or commercial use of human embryos leads to a demand for large numbers of ova. Thus, it is vital that researchers and policy-makers heed feminist concerns about embryo research and the new biomedical technologies it may yield. Given adequate information and appropriate procedural protections, women are capable of making autonomous decisions about donating ova or embryos for biomedical research. But regulatory safeguards are needed to ensure against their being coerced, deceived, or manipulated into becoming ovum or embryo donors. As Daniel Callahan has detailed, biomedical technology has reached the point where we can no longer afford to provide everyone with all of the innovative therapies that might prove beneficial (Callahan, 1989, p 523). Thus, questions about the just and cost-effective distribution of medical resources will become increasingly difficult and important. Among these questions will be whether it is wise or just to invest large sums in the development of innovative methods of assisting human reproduction. We must also consider the interests of future persons who may suffer because of the methods used to bring them into existence.(ABSTRACT TRUNCATED AT 400 WORDS)

Not “human” enough to be human but not “animal” enough to be animal – the case of the HFEA, cybrids and xenotransplantation in the UK

Unaddressed regulatory issues in xenotransplantation: a hypothetical example

Regulating embryo models in the UK

Embryo manipulation and experimentation

Human iPSC-Chimera Xenotransplantation and the Non-Identity Problem

A scientific case for revisiting the embryonic chicken model in biomedical research

Xenotransplantation in Australia: Development of the regulatory process

Solid organ xenotransplantation at the interface between research and clinical development: Regulatory aspects

Update on the ethical, legal and technical challenges of translating xenotransplantation

Potentiality switches and epistemic uncertainty: the Argument from Potential in times of human embryo-like structures

The use and disposal of stored embryos

Pre-persons, commodities or cyborgs: the legal construction and representation of the embryo

Innovation and regulation in human implant technologies: developing comparative approaches

Ethical analysis of the first porcine cardiac xenotransplantation

Borderlands of Life: IVF Embryos and the Law in the United States, United Kingdom, and Germany

Ethical and legislative advances in xenotransplantation for clinical translation: focusing on cardiac, kidney and islet cell xenotransplantation

Bioethics in human embryology: the double-edged sword of embryo research

Pluripotent Stem Cell-Derived In Vitro Gametogenesis and Synthetic Embryos—It Is Never Too Early for an Ethical Debate

Plans to Abolish Bodies Regulating Fertility Treatment and Human Tissues Are Discussed

Regulatory Challenges at the Intersection of Cellular and Medical Device Therapies in Europe: The Case of the Bioartificial Pancreas

On recent advances in human engineering Provocative trends in embryology, genetics, and regenerative medicine